Coronary stenting for myocardial infarction: its developmental trends

doi:10.3969/j.issn.2095-4344.2016.03.027

Abstract

Abstract:

BACKGROUND: Coronary stenting can effectively prevent the artery blood vessels against obstruction or stenosis due to fat accumulation and improve cardiac function in patients with myocardial infarction.
OBJECTIVE: To analyze the clinical trends of different types of coronary stents for myocardial infarction reported
from 2004 to 2015 in Medline, CNKI, Wanfang, ClinicalTrials.gov and Chinese Clinical Trial Register.
METHODS: The relevant articles addressing metal bare stents, drug-eluting stents, and biodegradable stents were retrieved using the keywords of “stent” and “myocardial infarction” in Chinese and English in Medline, CNKI, Wanfang, ClinicalTrials.gov and Chinese Clinical Trial Register followed by statistical analysis. The retrieval time was from 2004 to 2015, including 2004-2007, 2008-2011 and 2012-2015.
RESULTS AND CONCLUSION: (1) In Medline database, there were 720 clinical studies about coronary stenting for myocardial infarction published from 2004 to 2015. The number of articles addressing drug-eluting stents continued to increase from 2004 to 2007, 2008 to 2011 and 2012 to 2015. The number of articles addressing metal bare stents reached the peak from 2008 to 2011, and then decreased. Biodegradable stents appeared after 2008, and the number of relevant articles was increased gradually. In CNKI and Wanfang databases, the number of metal bare stents for myocardial infarction was at a lower level, while the number of drug-eluting stents was peaked from 2008 to 2011, and at that time, biodegradable stents were rarely reported in China. (2) In ClinicalTrials.gov, the number of clinical trials about metal bare stents for myocardial infarction was relatively low, the number of clinical trials about drug-eluting stents was reduced dramatically from 2012 to 2015, but the number of clinical trials about biodegradable stents for myocardial infarction had a rising trend.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Miao Lei, Liu Pei-liang . Coronary stenting for myocardial infarction: its developmental trends[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(3): 451-455.

Figures/Tables 4

References

[1] Burke AP, Virmani R. Pathophysiology of acute myocardial infarction. Med Clin North Am. 2007;91(4):553-572.

[2] Devlin RJ, Henry JA. Clinical review: Major consequences of illicit drug consumption. Crit. Care. 2008;12(1):202-202.

[3] Taghaddosi M, Dianati M, Fath Gharib Bidgoli J, et al. Delay and its Related Factors in Seeking Treatment in Patients with Acute Myocardial Infarction. ARYA Atherosclerosis. 2010;6(1):35-41.

[4] Ellis SG, Tendera M, De Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. New Engl J Med. 2008;358(21):2205-2217.

[5] Lukenda J, Biocina-Lukenda D. Stent, endovascular prosthesis, net or strut? What would British dentist Charles Stent (1807-1885) have to say on all this? Lijec Vjesn. 2009; 131(1-2):30-33.

[6] Kim MS, Dean LS. In-stent restenosis. Cardiovasc Ther. 2011; 29(3):190-198.

[7] Holmes DR, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56(17):1357-1365.

[8] Mauri L, Hsieh W H, Massaro JM, et al. Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents. New Engl J Med. 2007;356(10):1020-1029.

[9] Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015;65(23):2496-2507.

[10] Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228.

[11] Mieres J, Fernandez-Pereira C, Risau G, et al. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR). Cardiovasc Revasc Med. 2012;13(5):265-271.

[12] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574-651.

[13] Cao J, Gao JX, Wei LP, et al. Preliminary experience of coronary stent implantation: clinical analysis of 20 cases. Zhongguo Yiyao Daokan. 2009;11(2):323-324.

[14] Shi CL, Li X, Liu PL, et al. Primary experience of coronary artery stent implantation in the treatment of coronary heart disease. Shiyong Xin Nao Xueguan Bing Zazhi. 2013;21(1):130-131.

[15] Liu PL, Zhang M, Miao L, et al. XTRM-FIT coronary coated stent combined with tirofiban in the treatment of elderly patients with acute coronary syndrome. Zhongguo Shiyong Yikan. 2012;39(7):91-93.

[16] Liu PL, Yuan L, Miao L, et al. Effect of percutaneous coronary intervention on B brain natriuretic peptide and ventricular remodeling in patients with acute myocardial infarction. Zhongguo Shiyong Yikan. 2011;38(1):79-80.

[17] Li X, Liu PL, Zhang M, et al. Clinical study of percutaneous coronary intervention (PCI) in elderly patients with coronary heart disease. Zhongguo Shiyong Yiyao. 2012;7(5):77-78.

[18] Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009;5 Suppl F(F15-22.

[19] Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA. 2005;294(10):1215-1223.

[20] Menichelli M, Parma A, Pucci E, et al. Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol. 2007; 49(19):1924-1930.

[21] Violini R, Musto C, De Felice F, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. J Am Coll Cardiol. 2010;55(8):810-814.

[22] Kaltoft A, Kelbæk H, Thuesen L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2010;56(8):641-645.

[23] Wiebe J, Möllmann H, Most A, et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014;103(3):141-148.

[24] Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35(12):777-786.